21st Austria weekly - Marinomed 07/02/2024 [pic1]Marinomed: Biotech AG has enrolled the first patient in a clinical study to investigate lubricating properties of Carragelose eye drops patients diagnosed with mild moderate dry disease. While product holds valid certification under Medical Device Directive MDD supports switch new Regulation MDR. are planned launch 2024. Furthermore business development process for partnering outside is full swing. Next drops also allergen-blocking nasal spray published data demonstrating effectiveness prophylactic treatment allergic rhinitis symptoms nose on pre-print server October
EQS-News: Marinomed Biotech AG with important progress for Carragelose in 2024 finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
EQS-News: Marinomed Biotech AG / Key word: Study/Patent
Marinomed Biotech AG with important progress for Carragelose in 2024
07.02.2024 / 07:45 CET/CEST
The issuer is.
ClearPoint Neuro Inc. (CLPT) Announces First EU MDR Certification Success and Approval to Ship Product to Europe streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ClearPoint Neuro receives EU okay for devices, Calif. plant (NASDAQ:CLPT) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.